➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Boehringer Ingelheim
Johnson and Johnson
Moodys
Baxter
Medtronic

Last Updated: October 24, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR APREMILAST

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for apremilast

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00456092 ↗ Phase II Study With CC-10004 in Psoriatic Arthritis Completed Celgene Corporation Phase 2 2009-01-01 This study is to look at the preliminary efficacy and safety of CC-10004 vs placebo in patients with active psoriatic arthritis. The pharmacokinetics of the compound in patients will also be explored, and biopsies will be taken of the skin and the knee synovium to look at the activity of the drug in the relevant tissues.
NCT00521339 ↗ Apremilast Safety and PK Study in Recalcitrant Plaque Psoriasis Completed Celgene Corporation Phase 2 2007-08-01 The study will test the safety and tolerability of Apremilast twice a day in participants with recalcitrant plaque type psoriasis.
NCT00604682 ↗ Open-Label,Single-Arm Pilot Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Preliminary Efficacy of CC1004 in Subjects With Severe Plaque Type Psoriasis Completed Celgene Corporation Phase 2 2005-01-01 Open label study for patients with severe plaque type psoriasis. This study is looking to evaluate the pharmacodynamic effect of CC10004 when taken for 29 days in reducing the epidermal thickness in subjects with severe placque type psoriasis.
NCT00606450 ↗ Double-Blind, Randomized, Placebo-controlled Comparison of CC-10004 in Subjects With Moderate to Severe Plaque Type Psoriasis Completed Celgene Corporation Phase 2 2006-04-01 There is an unmet medical need for safe, effective oral therapy for moderate-to-severe psoriasis. CC-10004 will be evaluated in a controlled setting of a clinical study. The information obtained from the study will aid in the design of future clinical trials and to establish the safety and efficacy of CC-10004.
NCT00708916 ↗ Safety Study of Clinical and Immune Effects of Phosphodiesterase 4 (PDE-4) Inhibitor in Cutaneous Lupus Patients Completed Celgene Corporation Phase 1/Phase 2 2008-06-01 The purpose of this study is to determine the clinical and immunological effects of the phosphodiesterase type 4 inhibitor, CC-10004, on skin inflammation associated with cutaneous lupus erythematosus.
NCT00708916 ↗ Safety Study of Clinical and Immune Effects of Phosphodiesterase 4 (PDE-4) Inhibitor in Cutaneous Lupus Patients Completed New York University School of Medicine Phase 1/Phase 2 2008-06-01 The purpose of this study is to determine the clinical and immunological effects of the phosphodiesterase type 4 inhibitor, CC-10004, on skin inflammation associated with cutaneous lupus erythematosus.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for apremilast

Condition Name

Condition Name for apremilast
Intervention Trials
Psoriasis 20
Psoriatic Arthritis 14
Plaque Psoriasis 8
Healthy 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for apremilast
Intervention Trials
Psoriasis 38
Arthritis 19
Arthritis, Psoriatic 18
Dermatitis 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for apremilast

Trials by Country

Trials by Country for apremilast
Location Trials
United States 374
Canada 92
Japan 35
Australia 30
Germany 25
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for apremilast
Location Trials
California 25
Florida 24
New York 22
Texas 20
Illinois 18
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for apremilast

Clinical Trial Phase

Clinical Trial Phase for apremilast
Clinical Trial Phase Trials
Phase 4 21
Phase 3 27
Phase 2 36
[disabled in preview] 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for apremilast
Clinical Trial Phase Trials
Not yet recruiting 32
Completed 25
Recruiting 24
[disabled in preview] 18
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for apremilast

Sponsor Name

Sponsor Name for apremilast
Sponsor Trials
Celgene Corporation 50
Celgene 20
Amgen 5
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for apremilast
Sponsor Trials
Industry 83
Other 71
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Medtronic
Colorcon
Dow
Moodys
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.